Effect of two active compounds obtained from the essential oil of Cordia verbenacea on the acute inflammatory responses elicited by LPS in the rat paw

British Journal of Pharmacology

Volumn 151, Issue 5, 2007, Pages 618-627

  Medeiros, R ^a   Passos, G F ^a   Vitor, C E ^a   Koepp, J ^a   Mazzuco, T L ^a   Pianowski, L F ^b   Campos, M M ^c   Calixto, J B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b Pontifícia Universidade Católica Do Rio Grande Do Sul ^*  (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Bradykinin; Cordia verbenacea; Inflammation; Lipopolysaccharide; MAP kinases; Nuclear factor B; Trans caryophyllene; humulene

Indexed keywords

CARYOPHYLLENE; CYTOKINE; ESSENTIAL OIL; HUMULENE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KININ; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SESQUITERPENE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORDIA VERBENACEA; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; INFLAMMATION; LEUKOCYTE ACTIVATION; MALE; MEDICINAL PLANT; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; UPREGULATION;

EID: 34347352040     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707270     Document Type: Article

References (43)

1. Ahluwalia A, Perretti M (1999). B1 receptors as a new inflammatory target. Could this B the 1? Trends Pharmacol Sci 20: 100-104.
2. Beutler B (2002). LPS in microbial pathogenesis: promise and fulfilment. J Endotoxin Res 8: 329-335.
3. Beutler B, Rietschel ET (2003). Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3: 169-176.
4. Calixto JB, Cabrini DA, Ferreira J, Campos MM (2000). Kinins in pain and inflammation. Pain 87: 1-5.
5. Calixto JB, Campos MM, Otuki MF, Santos AR (2004a). Anti-inflammatory compounds of plant origin. Part II. Modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 70: 93-103.
6. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, Campos MM (2004b). Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 143: 803-818.
7. Calixto JB, Otuki MF, Santos AR (2003). Anti-inflammatory compounds of plant origin. Part I. Action on arachidonic acid pathway, nitric oxide and nuclear factor kappa B (NF-kappaB). Planta Med 69: 973-983.
8. Campos MM, Leal PC, Yunes RA, Calixto JB (2006). Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammatory and pain diseases. Trends Pharmacol Sci 27: 646-651.
9. Campos MM, Souza GE, Calixto JB (1999). In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways. Br J Pharmacol 127: 1851-1859.
10. Conley RK, Wheeldon A, Webb JK, DiPardo RM, Homnick CF, Bock MG et al. (2005). Inhibition of acute nociceptive responses in rat spinal cord by a bradykinin B1 receptor antagonist. Eur J Pharmacol 527: 44-51.
11. Cragg GM, Newman DJ, Snader KM (1997). Natural products in drug discovery and development. J Nat Prod 60: 52-60.
12. de Carvalho Jr PM, Rodrigues RF, Sawaya AC, Marques MO, Shimizu MT (2004). Chemical composition and antimicrobial activity of the essential oil of Cordiaverbenacea DC. J Ethnopharmacol 95: 297-301.
13. De Smet PA (1997). The role of plant-derived drugs and herbal medicines in healthcare. Drugs 54: 801-840.
14. Derevianko A, Graeber T, D'Amico R, Simms HH (1998). The role of neutrophil-derived oxidants as second messengers in interleukin 1beta-stimulated cells. Shock 10: 54-61.
15. El Sayah M, Medeiros R, Fernandes ES, Campos MM, Calixto JB (2006). Mechanisms underlying lipopolysaccharide-induced kinin B1 receptor up-regulation in the pig iris sphincter in vitro. Mol Pharmacol 69: 1701-1708.
16. Ferreira J, Beirith A, Mori MA, Araujo RC, Bader M, Pesquero JB et al. (2005). Reduced nerve injury-induced neuropathic pain in kinin B1 receptor knock-out mice. J Neurosci 25: 2405-2412.
17. Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, Maruani J et al. (2004). SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6- methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2, 6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N- methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309: 661-669.
18. Grutkoski PS, D'Amico R, Ayala A, Simms HH (1999). IL-1beta stimulation induces paracrine regulation of PMN function and apoptosis. Shock 12: 373-381.
19. Hoffmann TF, Kubler J, Messmer K (1998). Selective bradykinin B1 receptor block in ischemia/reperfusion of the rat pancreas. Langenbecks Arch Chir Suppl Kongressbd 115: 443-446.
20. Hwang D, Jang BC, Yu G, Boudreau M (1997). Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages. Biochem Pharmacol 54: 87-96.
21. Karin M (2005). Inflammation-activated protein kinases as targets for drug development. Proc Am Thorac Soc 2: 386-390; discussion 394-395.
22. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA (2001). Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7: 1291-1297.
23. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL (2005). International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57: 27-77.
24. Marceau F, Regoli D (2004). Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3: 845-852.
25. Medeiros R, Cabrini DA, Calixto JB (2001). The 'in vivo' and 'ex vivo' roles of cylcooxygenase-2, nuclear factor-kappaB and protein kinases pathways in the up-regulation of B1 receptor-mediated contraction of the rabbit aorta. Regul Pept 97: 121-130.
26. Medeiros R, Cabrini DA, Ferreira J, Fernandes ES, Mori MA, Pesquero JB et al. (2004). Bradykinin B1 receptor expression induced by tissue damage in the rat portal vein: a critical role for mitogen-activated protein kinase and nuclear factor-kappaB signaling pathways. Circ Res 94: 1375-1382.
27. Miyake K (2004). Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 12: 186-192.
28. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A (2005). The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99: 6-38.
29. Ni A, Chao L, Chao J (1998). Transcription factor nuclear factor kappaB regulates the inducible expression of the human B1 receptor gene in inflammation. J Biol Chem 273: 2784-2791.
30. Passos GF, Fernandes ES, Campos MM, Araujo JG, Pesquero JL, Souza GE et al. (2004). Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J Immunol 172: 1839-1847.
31. Passos GF, Fernandes ES, Cunha FM, Ferreira J, Pianowski LF, Campos MM et al. (2007). Anti-inflammatory and anti-allergic properties of the essential oil and active compounds from Cordia verbenacea. J Ethnopharmacol 21: 323-333.
32. Porreca F, Vanderah TW, Guo W, Barth M, Dodey P, Peyrou V et al. (2006). Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl) phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]methylamino]ethoxy] -N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist. J Pharmacol Exp Ther 318: 195-205.
33. Prado GN, Taylor L, Zhou X, Ricupero D, Mierke DF, Polgar P (2002). Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J Cell Physiol 193: 275-286.
34. Regoli D, Barabe J (1980). Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1-46.
35. Rocha AC, Fernandes ES, Passos GF, Calixto JB, Campos MM (2005). Assessment of TNFalpha contribution to the functional upregulation of kinin B(1) receptors in the mouse paw after treatment with LPS. Int Immunopharmacol 5: 1593-1600.
36. Rosenbaum JT, Boney RS (1991). Use of a soluble interleukin-1 receptor to inhibit ocular inflammation. Curr Eye Res 10: 1137-1139.
37. Rosenbaum JT, Enkel H (1987). Stimulus-specific effects of endotoxin on superoxide production by rabbit polymorphonuclear leukocytes. Yale J Biol Med 60: 391-396.
38. Rossner M, Yamada KM (2004). What's in a picture? The temptation of image manipulation. J Cell Biol 166: 11-15.
39. Sabourin T, Morissette G, Bouthillier J, Levesque L, Marceau F (2002). Expression of kinin B(1) receptor in fresh or cultured rabbit aortic smooth muscle: role of NF-kappa B. Am J Physiol Heart Circ Physiol 283: H227-H237.
40. Schanstra JP, Bataille E, Marin Castano ME, Barascud Y, Hirtz C, Pesquero JB et al. (1998). The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest 101: 2080-2091.
41. Surh YJ, Kundu JK, Na HK, Lee JS (2005). Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr 135: 2993S-3001S.
42. Thorlacius H, Lindbom L, Raud J (1997). Cytokine-induced leukocyte rolling in mouse cremaster muscle arterioles in P-selectin dependent. Am J Physiol 272: H1725-H1729.
43. Vianna RM, Ongali B, Regoli D, Calixto JB, Couture R (2003). Upregulation of kinin B1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence. Br J Pharmacol 138: 13-22.